Alembic Pharmaceuticals Ltd
NSE:APLLTD
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Price:
646.55
INR
-4.54%
Market Closed
Market Cap:
₹127.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Alembic Pharmaceuticals Ltd
NSE:APLLTD
|
IN |
|
Zhen Ding Technology Holding Ltd
TWSE:4958
|
KY |
|
Grinm Advanced Materials Co Ltd
SSE:600206
|
CN |
|
Ningbo Exciton Technology Co Ltd
SZSE:300566
|
CN |
|
Quantafuel ASA
OSE:QFUEL
|
NO |
|
B
|
Bms Birlesik Metal Sanayi ve Ticaret AS
IST:BMSTL.E
|
TR |
|
Koc Holding AS
IST:KCHOL.E
|
TR |
|
R S Software (India) Ltd
NSE:RSSOFTWARE
|
IN |
|
Beijing Zhidemai Technology Co Ltd
SZSE:300785
|
CN |
|
J
|
Jiangxi Sunshine Dairy Co Ltd
SZSE:001318
|
CN |
|
G
|
Guangdong Huiyun Titanium Industry Co Ltd
SZSE:300891
|
CN |
|
K
|
KCC Engineering & Construction Co Ltd
KOSDAQ:021320
|
KR |
Relative Value
The Relative Value of one
APLLTD
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 646.55 INR,
Alembic Pharmaceuticals Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
APLLTD Relative Value
HIDDEN
Multiples Across Competitors
APLLTD Competitors Multiples
Alembic Pharmaceuticals Ltd Competitors
Alembic Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Alembic Pharmaceuticals Ltd
NSE:APLLTD
|
127.1B INR | 1.7 | 20.2 | 12.2 | 16.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 13.1 | 41.3 | 27.9 | 29.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.5B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.8 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.1B GBP | 4.9 | 28 | 15.6 | 22 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
288B USD | 4.4 | 15.8 | 9.8 | 11.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.3B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.5B USD | 2.4 | 16.4 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
